Varsha Gandhi, PhD, on Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opening Session Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

Cost of Care

The ASCO Post Staff

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Dec

Today In Oncology

Varsha Gandhi, PhD, on Ibrutinib

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opening Session Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer

Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS

Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL

Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL

Experimental CAR T-Cell Therapy Shows High Efficacy and a Favorable Safety Profile in Multiple Myeloma